A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions
- Acronyms MAVERICK-HCM
- Sponsors MyoKardia
- 14 Nov 2018 Trial design presented at the 91st Annual Scientific Sessions of the American Heart Association
- 05 Nov 2018 According to a MyoKardia media release, data from this trial will be presented at the American Heart Association (AHA) Scientific Sessions 2018 .
- 05 Nov 2018 According to a MyoKardia media release, adaitional Clinical Evidence from this study is Expected in 2H 2019.